Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Immuron ( (IMRN) ).
On October 17, 2025, Immuron Limited announced a proposed issue of 1,133,840 ordinary fully paid securities through a placement. This initiative aims to support the company’s research and development activities and provide ongoing working capital. The shares were purchased by US investors from Immuron’s US At-The-Market (ATM) facility, managed by H.C. Wainwright & Co., which is a low fee, no discount facility. This strategic move is expected to bolster Immuron’s financial resources, potentially enhancing its market position and operational capabilities.
The most recent analyst rating on (IMRN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Neutral.
Immuron’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis provides some positive momentum, but valuation remains a concern with a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited is an Australian-based company operating in the biotechnology industry, focusing on the development and commercialization of oral immunotherapeutics for the treatment of gut-mediated diseases.
Average Trading Volume: 77,257
Technical Sentiment Signal: Hold
Current Market Cap: $14.58M
Learn more about IMRN stock on TipRanks’ Stock Analysis page.